Optimizing the dose of imatinib for treatment of gastrointestinal stromal tumours: Lessons from the phase 3 trials
- 31 March 2008
- journal article
- research article
- Published by Elsevier BV in European Journal Of Cancer
- Vol. 44 (4), 501-509
- https://doi.org/10.1016/j.ejca.2007.11.021
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Current perspectives on the epidemiology of gastrointestinal stromal tumoursEuropean Journal of Cancer Supplements, 2006
- Gastrointestinal Stromal Tumours: Consensus Statement on Diagnosis and TreatmentCanadian Journal of Gastroenterology, 2006
- Incidence of gastrointestinal stromal tumours is underestimated: Results of a nation-wide studyEuropean Journal Of Cancer, 2005
- Consensus meeting for the management of gastrointestinal stromal tumors Report of the GIST Consensus Conference of 20–21 March 2004, under the auspices of ESMOAnnals of Oncology, 2005
- Gastrointestinal stromal tumors: The incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate eraCancer, 2005
- Update on the Biology and Therapy of Gastrointestinal Stromal TumorsCancer Control, 2005
- Biology of Gastrointestinal Stromal TumorsJournal of Clinical Oncology, 2004
- PDGFRA Activating Mutations in Gastrointestinal Stromal TumorsScience, 2003
- Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitorBlood, 2000
- Gain-of-Function Mutations of c- kit in Human Gastrointestinal Stromal TumorsScience, 1998